Laura Brege
At a glance: Laura Brege is Director at Mirum Pharmaceuticals (MIRM). Their latest SEC Form 4, filed Nov 13, 2026, reported a sale of $1.0M. On file: 0 purchase lines ($0) and 2 sale lines ($1.3M).
Disclosed holdings: about $1.5M of MIRM stock: 15,703 shares reported on their latest Form 4 (filed Nov 13, 2026), valued at the Nov 13, 2026 close of $93.99. This counts only MIRM shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.
Director at Mirum Pharmaceuticals, Inc. (MIRM)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
Every purchase since 2024
From the SEC's insider data sets: each open-market buy by Laura Brege, matched to how the stock did over the next 90 days against the S&P 500.
1 of 1 buy beat the S&P 500 (100%), median +13.8% vs. the index. Small sample: treat with care. All insider buys: 46%.
| Stock | Filed | 90 days vs. S&P 500 |
|---|---|---|
| PCRX | Aug 19, 2024 | +13.8% |
Buys made close together in one stock count once. Price-only returns; history, not a prediction.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Nov 13 NewSEC | MIRMMirum Pharmaceuticals, Inc. | Sell | 10,90718,963 held (−37%) | $94.05 | $1.0M | -0.1% |
| Nov 13 NewSEC | MIRMMirum Pharmaceuticals, Inc. | Sell | 3,26015,703 held (−17%) | $94.74 | $309K | -0.8% |
- Sell
Director Laura Brege sold $1.0M of MIRM at $94.05 — cuts the stake by 37%.
Follow Laura Brege
Get one email when Laura Brege files a new purchase or sale. Free.
At most one email a day about Laura Brege, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.